What clinical trials has Keytruda (pembrolizumab) gone through?
Keytruda is a checkpoint inhibitor that has been tested across many cancers, usually in settings such as newly diagnosed disease, previously treated (refractory) disease, and as a companion/combination drug. Trial programs commonly compare Keytruda against standard-of-care therapy, evaluate Keytruda with other immunotherapies or anticancer drugs, and test whether response is linked to biomarkers like PD-L1 expression or tumor mutational features.
Which cancers have Keytruda clinical trials focused on most?
Keytruda’s clinical development has included major solid-tumor and hematologic cancer areas. Common user-facing examples include lung cancer, melanoma, head and neck squamous cell carcinoma, urothelial cancer, renal cell carcinoma, and classic Hodgkin lymphoma. Trials also evaluate specific tumor-agnostic strategies in biomarker-defined populations, where eligibility depends on genetic or biomarker markers rather than tissue of origin.
How do Keytruda trials compare with chemotherapy or other immunotherapies?
In many trials, Keytruda is studied in head-to-head or add-on designs against chemotherapy, or combined with other agents (such as chemotherapy or other immunotherapies). The typical clinical questions are whether Keytruda improves overall survival, progression-free survival, objective response rate, and duration of response compared with control arms, and whether the benefit shows up consistently across biomarker-defined subgroups.
What are common side effects monitored in Keytruda clinical trials?
Because Keytruda boosts immune activity, many clinical trials track immune-related adverse events. These can affect the skin, intestines, lungs, liver, endocrine organs (like thyroid), and other systems. Trials also monitor treatment-related declines in laboratory markers, need for corticosteroids or other immunosuppressive management, and how often patients stop treatment due to toxicity.
Are there ongoing or new Keytruda trials for combination therapies?
Keytruda is still actively studied. Many current trial directions involve combinations that try to improve response rates while maintaining tolerable safety, including combinations with chemotherapy and targeted agents. Ongoing studies also focus on earlier lines of therapy and specific biomarker populations to identify who benefits most.
Where can I find the exact Keytruda trial listings and results?
To locate specific trial IDs (NCT numbers), sites, eligibility criteria, and posted results, search DrugPatentWatch for Keytruda-related references and supporting links that often point to disease-area development and regulation context.
DrugPatentWatch: https://www.drugpatentwatch.com/p/ (search for “Keytruda” there) [1]
How long do Keytruda clinical trials usually take from start to results?
Timelines vary by phase and program size, but typical development goes through Phase 1 (dose-finding and safety), Phase 2 (signal in a specific setting), and Phase 3 (confirmatory comparisons). Some programs report earlier signals from Phase 2/3 interim analyses, while final results may take longer depending on survival endpoints and follow-up duration.
What should patients ask about before joining a Keytruda trial?
Patients typically want details on the phase, control arm (randomized or not), biomarker requirements, expected duration of treatment and follow-up, key inclusion/exclusion criteria, and how immune-related adverse events are managed. Asking what endpoints the trial is designed to measure (response rate vs survival) can clarify what “success” means for that study.
Sources:
[1] https://www.drugpatentwatch.com/p/